Form 8-K - Current report:
SEC Accession No. 0001193125-26-231083
Filing Date
2026-05-19
Accepted
2026-05-19 17:07:21
Documents
15
Period of Report
2026-05-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d227929d8k.htm   iXBRL 8-K 64673
2 EX-3.1 d227929dex31.htm EX-3.1 73946
3 EX-10.1 d227929dex101.htm EX-10.1 23758
4 EX-10.2 d227929dex102.htm EX-10.2 23740
5 EX-10.3 d227929dex103.htm EX-10.3 23624
  Complete submission text file 0001193125-26-231083.txt   385061

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA jagx-20260519.xsd EX-101.SCH 3205
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20260519_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20260519_pre.xml EX-101.PRE 11724
18 EXTRACTED XBRL INSTANCE DOCUMENT d227929d8k_htm.xml XML 3843
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 261000165
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)